Carbetocin vs. Oxytocin: Preventing Postpartum Hemorrhage | Cureus

A study published in September 2025 indicates carbetocin demonstrates reduced blood loss and lower rates of postpartum hemorrhage (PPH) compared to oxytocin across all birth types, even after statistical adjustments. The findings, published in Obstetrics & Gynecology, add to a growing body of evidence supporting carbetocin as a viable alternative to oxytocin in preventing excessive bleeding after childbirth.

Postpartum hemorrhage remains a leading cause of maternal mortality globally. Oxytocin has long been the standard preventative treatment, but its effectiveness is contingent on proper storage and administration, particularly in resource-limited settings. Carbetocin, a synthetic analogue of oxytocin, offers the advantage of being heat-stable, simplifying storage and distribution.

Research published in 2018 by the New England Journal of Medicine highlighted the critical need for effective PPH prevention, noting that postpartum hemorrhage is the most common cause of maternal death. This earlier study contributed to the exploration of carbetocin as a potential solution, particularly in areas where maintaining a consistent cold chain for oxytocin is challenging.

Guidance from the International Federation of Gynecology and Obstetrics (FIGO), updated in March 2023, recommends carbetocin specifically for PPH prevention and explicitly advises against its utilize for labor induction or augmentation. This focused recommendation underscores the specific role carbetocin plays in managing postpartum bleeding risks.

A 2012 Cochrane review further investigated carbetocin’s efficacy, finding it associated with less blood loss than syntometrine – a combination of oxytocin and ergometrine – in women undergoing vaginal deliveries. However, the review also noted syntometrine’s association with more side effects.

The recent 2025 study builds on this existing research by examining carbetocin’s performance across a broader range of birth scenarios. Researchers assessed outcomes across vaginal deliveries, cesarean sections, and other birth types, consistently observing a reduction in blood loss and PPH incidence with carbetocin use.

Despite the accumulating evidence, the role of carbetocin in global maternal health strategies remains a subject of ongoing evaluation and implementation. Further research is expected to refine protocols for carbetocin administration and assess its long-term impact on maternal morbidity and mortality rates.